Mutant mouse having a disrupted TNFRp55
AssigneeThe Ontario Cancer Institute
InventorTak W. Mak
Life of this patent
Estimating the term…
Loading patent…
AssigneeThe Ontario Cancer Institute
InventorTak W. Mak
Estimating the term…
The multiple biological activities of tumor necrosis factor (TNF) are mediated by two distinct cell surface receptors of 55 and 75 kDa. Mutant mice of the invention lacking tumor necrosis factor receptor (TNFR) p55 still express functional TNFRp75 molecules at the cell surface. Normal weight and size of the mutant mice are not altered. Thymocyte development and lymphocyte populations are normal, and clonal deletion of potentially self-reactive T cells is not impaired. Activation of the nuclear transcription factor .kappa.B (NF-.kappa.B), however, is completely abrogated after stimulation with TNF. Moreover, TNFRp55 mutant mice are protected from septic shock induced by bacterial endotoxin or superantigen, but Listeria clearance is severely impaired and mutant mice easily succumb to Listeria infection. Thus, the two TNF receptors are not redundant, are independently controlled, and play different roles in normal and pathological physiology.
A mutant mouse comprising a TNFRp55 gone having a disruption in as least one exon thereof, wherein (1) said disruption has been introduced into the genome of said mouse by homologous recombination in an embryonic stem cell, and (2) said disruption provides a null mutation which results in no expression of tumor necrosis factor receptor p55 (TNFRp55) by said mouse, and further wherein said mouse lacks the ability to bind human TNF.alpha. and is more susceptible to infection by Listeria monocytogenes than a mouse lacking said disruption.
The embryonic stem (ES) cell line having a disrupted TNFRp55 gene, ATCC Accession No. CRL 11379.
Dependencies are inferred from the claim text.